BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
February 08, 2023 09:00 ET
|
BioRestorative Therapies, Inc
--Patent provides protection in key international markets for BioRestorative’s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Feb. 08,...
BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
October 20, 2022 09:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 22, 2022 07:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
April 18, 2022 08:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification
April 04, 2022 08:00 ET
|
BioRestorative Therapies, Inc
Certification Gives BioRestorative Therapies Clinical Grade Manufacturing Capabilities MELVILLE, N.Y., April 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...
BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway
February 07, 2022 09:00 ET
|
BioRestorative Therapies, Inc
BioRestorative Provides Update on its Active Phase 2 Clinical Trial MELVILLE, N.Y., Feb. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:...
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
February 02, 2022 08:00 ET
|
BioRestorative Therapies, Inc
Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds MELVILLE, N.Y., Feb. 02, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...
BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance
January 11, 2022 06:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies,...
BioRestorative Therapies Discusses Upcoming Annual Meeting of Stockholders
August 11, 2021 08:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 11, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today...
BioRestorative Therapies to Present at the Emerging Growth Conference on June 9, 2021
June 07, 2021 06:00 ET
|
BioRestorative Therapies, Inc
BioRestorative Therapies invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the online Emerging Growth Conference. ...